Cargando…
Reference Values to Assess Hemodilution and Warn of Potential False-Negative Minimal Residual Disease Results in Myeloma
SIMPLE SUMMARY: Although the majority of patients with myeloma who achieve undetectable minimal residual disease show prolonged survival, some of them relapse shortly afterwards. False-negative results due to hemodiluted bone marrow samples could explain this inconsistency, but there is no guidance...
Autores principales: | Puig, Noemí, Flores-Montero, Juan, Burgos, Leire, Cedena, María-Teresa, Cordón, Lourdes, Pérez, José-Juan, Sanoja-Flores, Luzalba, Manrique, Irene, Rodríguez-Otero, Paula, Rosiñol, Laura, Martínez-López, Joaquín, Mateos, María-Victoria, Lahuerta, Juan-José, Bladé, Joan, San Miguel, Jesús F., Orfao, Alberto, Paiva, Bruno |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8508317/ https://www.ncbi.nlm.nih.gov/pubmed/34638406 http://dx.doi.org/10.3390/cancers13194924 |
Ejemplares similares
-
Detection of Circulating Tumor Plasma Cells in Monoclonal Gammopathies: Methods, Pathogenic Role, and Clinical Implications
por: Sanoja-Flores, Luzalba, et al.
Publicado: (2020) -
Measurable residual disease in multiple myeloma: ready for clinical practice?
por: Burgos, Leire, et al.
Publicado: (2020) -
Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma
por: Medina, Alejandro, et al.
Publicado: (2020) -
FlowCT for the analysis of large immunophenotypic data sets and biomarker discovery in cancer immunology
por: Botta, Cirino, et al.
Publicado: (2022) -
P819: CONTRIBUTION OF IMMUNOPHENOTYPING OF BONE MARROW B CELLS AND PLASMA CELLS IN THE DIAGNOSTIC CLASSIFICATION OF INDIVIDUALS PRESENTING WITH A SERUM M-PROTEIN
por: Pérez-Escurza, Oihane, et al.
Publicado: (2023)